Frontier Biotechnologies Inc. Class ASSE: 688221

Announcement on Voluntary Disclosure of the Notice of Acceptance for Registration and Marketing License of FB3002 Loxoprofen Sodium Patches Obtained for Drug Manufactured in China

· Issued by Frontier Biotechnologies Inc. Class A via Shanghai Stock Exchange
Announcement on Voluntary Disclosure of the Notice of Acceptance for Registration and Marketing License of FB3002 Loxoprofen Sodium Patches Obtained for Drug Manufactured in China

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Company analysis